Integrated BioPharma, Inc. (INBP)
OTCMKTS · Delayed Price · Currency is USD
0.2900
+0.0170 (6.23%)
Feb 20, 2026, 3:59 PM EST

Integrated BioPharma Income Statement

Millions USD. Fiscal year is Jul - Jun.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Jun '25 Jun '24 Jun '23 Jun '22 Jun '21
52.0954.3550.3250.6756.2563.56
Revenue Growth (YoY)
-0.06%8.02%-0.70%-9.91%-11.51%20.45%
Cost of Revenue
48.0248.7946.4346.6149.6954.08
Gross Profit
4.075.563.884.066.559.48
Selling, General & Admin
3.493.543.633.943.813.7
Operating Expenses
3.493.543.633.943.813.7
Operating Income
0.582.020.250.122.755.78
Interest Expense
-0.05-0.05-0.05-0.01-0.13-0.26
Interest & Investment Income
0.130.090.07---
Other Non Operating Income (Expenses)
00-0-0.010.010.06
EBT Excluding Unusual Items
0.672.060.270.12.635.59
Gain (Loss) on Sale of Investments
-----0.060
Gain (Loss) on Sale of Assets
----0.02-
Asset Writedown
0.03-----
Other Unusual Items
-----1.66
Pretax Income
0.72.060.270.12.67.25
Income Tax Expense
0.91.250.160.13-1.24-0.77
Net Income
-0.210.810.11-0.033.848.01
Net Income to Common
-0.210.810.11-0.033.848.01
Net Income Growth
-621.43%---52.10%95.06%
Shares Outstanding (Basic)
313030303030
Shares Outstanding (Diluted)
313131303232
Shares Change (YoY)
-1.62%0.95%3.08%-7.34%0.65%3.07%
EPS (Basic)
-0.010.030.00-0.000.130.27
EPS (Diluted)
-0.010.030.00-0.000.120.25
EPS Growth
-635.32%---52.00%92.31%
Free Cash Flow
2.821.870.391.123.612.76
Free Cash Flow Per Share
0.090.060.010.040.110.09
Gross Margin
7.81%10.23%7.72%8.01%11.65%14.92%
Operating Margin
1.11%3.72%0.50%0.24%4.88%9.10%
Profit Margin
-0.40%1.49%0.22%-0.07%6.82%12.61%
Free Cash Flow Margin
5.42%3.45%0.78%2.20%6.41%4.33%
EBITDA
0.882.340.560.473.086.12
EBITDA Margin
1.69%4.30%1.11%0.93%5.48%9.63%
D&A For EBITDA
0.310.320.310.350.340.34
EBIT
0.582.020.250.122.755.78
EBIT Margin
1.11%3.72%0.50%0.24%4.88%9.10%
Effective Tax Rate
129.64%60.81%58.21%134.00%--
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.